S1RP34.SA Sarepta Therapeutics Inc.

Healthcare Biotechnology Sao Paulo Exchange
5.07 BRL
Close of Nov 5, 2026
3.75 6.40
Market cap
BRL 10.7B
P/E
-
P/B
1.29x
ROE
42.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is S1RP34.SA undervalued?

Graham number

The Graham number of Sarepta Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sarepta Therapeutics Inc. fundamental analysis

No fundamental analysis for Sarepta Therapeutics Inc. yet.

Sarepta Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sarepta Therapeutics Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed…

Full company profile